<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813720</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0202</org_study_id>
    <nct_id>NCT02813720</nct_id>
  </id_info>
  <brief_title>Distal Erosions and Nail Psoriasis</brief_title>
  <acronym>PSUPSO</acronym>
  <official_title>Distal Phalangeal Bone Involvement Observed by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) in Patients With Nail Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nearly 30% of patients with cutaneous psoriasis (PsO) developed psoriatic arthritis (PsA).
      Among these patients 20 % will have severe destructive arthritis. The risk of developing PsA
      is significantly higher in patients with nail involvement (OR = 2.24; 95% CI [1.26-3.98]).
      The risk is particularly high for the peripheral form of PsA and onycholysis (OR=2.80; 95% CI
      [1.34-5.85]).

      Thus the investigators wanted to test the hypothesis that onycholysis, in patients without
      PsA, is a potential clinical marker of subclinical distal enthesopathy and, by extension, of
      bone micro-structural alterations.

      Patients and Methods

      The investigators will recruit 4 groups of subjects:

        1. Patients with peripheral PsA,

        2. Patients with psoriatic nail onycholysis,

        3. Patients with PsO only

        4. Healthy match control subjects. The investigators will assess the presence of
           enthesopathy by ultrasonography and bone structural damages (by HR-pQCT) in all subjects
           at baseline and 4 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>distal phalangeal bone erosion of the 2 index fingers of the hand</measure>
    <time_frame>at baseline and after 4 years of follow-up</time_frame>
    <description>assessment by HR-pQCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>enthesopathy of the 2 index fingers of the hand</measure>
    <time_frame>at baseline and after 4 years of follow-up</time_frame>
    <description>assessment by ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid factors</measure>
    <time_frame>Biomarkers are assessed at baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with peripheral PsA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with psoriatic nail onycholysis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with PsO only</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy match control subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HR-pQCT High resolution peripheral quantitative CT-scan</intervention_name>
    <description>HR-pQCT is a powerful device providing low dose irradiation already used in bone field.
It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density.</description>
    <arm_group_label>Patients with peripheral PsA</arm_group_label>
    <arm_group_label>Patients with psoriatic nail onycholysis</arm_group_label>
    <arm_group_label>Patients with PsO only</arm_group_label>
    <arm_group_label>Healthy match control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Serum and plasma Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PSUPSO is a prospective study. Diagnosis of PsA is based on the CASPAR criteria (Taylor
        2006). PASI, NAPSI and NAPSI target are recorded. PsO patients are gender and age matched
        with onycholysis patients patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults over 18 years and until 65 years

          -  both gender

          -  covered by the French National Insurance

          -  subjects entering one of the 4 groups.

        Exclusion Criteria:

          -  Treatment by biological agents are an exclusion criteria for PsO, onycholysis and
             control patients.

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrille Confavreux, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyrille Confavreux, MD PHD</last_name>
    <phone>(0)4 72 11 74 79</phone>
    <phone_ext>+33</phone_ext>
    <email>cyrille.confavreux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline Coutisson, clinical research assistant</last_name>
    <phone>(0)4 72 11 74 46</phone>
    <phone_ext>+33</phone_ext>
    <email>centre.prevention@wanadoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre des Métastases Osseuses (CEMOS) Pavillon F - Rhumatology Hôpital Edouard Herriot, 5 place d'Arsonval</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrille Confavreux, MD PHD</last_name>
      <phone>(0)4 72 11 74 79</phone>
      <phone_ext>+33</phone_ext>
      <email>cyrille.confavreux@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Céline Coutisson, clinical research assistant</last_name>
      <phone>(0)4 72 11 74 46</phone>
      <phone_ext>+33</phone_ext>
      <email>centre.prevention@wanadoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erosions</keyword>
  <keyword>Onycholysis</keyword>
  <keyword>HR-pQCT</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

